MediciNova Presents New Data And Results Of Phase 1b/2a Clinical Trial Of MN-166 At ASCO Meeting
MediciNova Presents New Data And Results Of Phase 1b/2a Clinical Trial Of MN-166 At ASCO Meeting
The highlights of presentation are as follows:
演示的亮点如下：
The primary endpoints were safety and tolerability of MN-166 and TMZ combination treatment and the efficacy of combination treatment.
MN-166和TMZ组合治疗的主要终点是安全性和耐受性，以及组合治疗的疗效。
The combination of Temozolomide (TMZ) and MN-166 was safe and well tolerated. No unexpected adverse effects were observed in both new GBM and recurrent GBM patients. Most reported adverse events were Lymphopenia, Leukopenia, Thrombocytopenia and Neutropenia.
Temozolomide（TMZ）和MN-166的组合治疗是安全和耐受的。在新的GBM和复发性GBM患者中均未观察到意外的不良反应。大多数报告的不良事件是淋巴细胞减少症、白细胞减少症、血小板减少症和中性粒细胞减少症。
Preclinical data has shown improved survival with the combination of Ibudilast and PD-1 or PD-L1 antibody therapy compared to treatment with ibudilast alone or PD-1/PD-L1 antibody alone, suggesting a potential promising therapeutic benefit of this combination.
临床前数据显示，与仅使用ibudilast或PD-1/PD-L1抗体单独治疗相比，使用Ibudilast和PD-1或PD-L1抗体疗法的组合治疗可以改善生存率，表明该组合可能具有潜在的治疗益处。